Haematology-Oncology · Clinical trials
Diffuse Large B-Cell Lymphoma (DLBCL) Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About diffuse large b-cell lymphoma (dlbcl) — and why its trials are hard
DLBCL is the most common aggressive non-Hodgkin lymphoma, arising from mature B cells and often curable with frontline chemoimmunotherapy. The addition of the anti-CD20 antibody rituximab to CHOP chemotherapy (R-CHOP) in the late 1990s transformed outcomes and remained the standard of care for two decades, curing roughly 60% of patients. In 2023 pola-R-CHP (substituting the anti-CD79b antibody-drug conjugate polatuzumab vedotin for vincristine) became the first regimen to improve on R-CHOP in the frontline setting. For relapsed/refractory disease, CD19-directed CAR T-cell therapies (axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel) deliver durable remissions, with axi-cel and liso-cel now approved in second line for early relapse. Additional relapsed options include the CD19 antibody tafasitamab plus lenalidomide, the ADC loncastuximab tesirine, and CD20xCD3 bispecific antibodies epcoritamab and glofitamab. Prognosis is stratified by the International Prognostic Index, cell-of-origin, and double-hit/high-grade genetics, which identify patients needing intensified or novel approaches.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Rituximab (with CHOP) (Rituxan) | 1997 | First-line DLBCL (R-CHOP), landmark | GELA LNH-98.5 / MInT | Overall survival | R-CHOP improved OS and cure rates by ~10-15 percentage points vs CHOP; foundational standard of care |
| Polatuzumab vedotin (with R-CHP) (Polivy) | 2023 | First-line DLBCL (IPI 2-5) | POLARIX | Progression-free survival | 2-year PFS 76.7% vs 70.2% for R-CHOP (HR ~0.73) |
| Axicabtagene ciloleucel (Yescarta) | 2017 | R/R DLBCL after >=2 lines (later 2nd line) | ZUMA-1 (2L: ZUMA-7) | Objective/complete response | ORR ~83%, CR ~58%; ZUMA-7 improved event-free survival vs salvage/transplant |
| Lisocabtagene maraleucel (Breyanzi) | 2021 | R/R DLBCL (also 2nd line) | TRANSCEND NHL-001 (2L: TRANSFORM) | Objective/complete response | ORR ~73%, CR ~53% |
| Tafasitamab + lenalidomide (Monjuvi) | 2020 | R/R DLBCL, transplant-ineligible | L-MIND | Objective response rate | ORR ~55%, CR ~37-40% |
| Epcoritamab (Epkinly) | 2023 | R/R DLBCL after >=2 lines | EPCORE NHL-1 | Objective/complete response | ORR ~63%, CR ~39% (accelerated approval) |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in diffuse large b-cell lymphoma (dlbcl) development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Ibrutinib (+ R-CHOP) — PHOENIX | Failed to improve event-free/overall survival in non-GCB DLBCL overall | Added toxicity, especially in patients >60 who could not complete R-CHOP; benefit limited to younger subgroup only |
| Obinutuzumab (G-CHOP) — GOYA | Did not improve PFS vs R-CHOP in first-line DLBCL | No meaningful advantage over rituximab despite higher CD20 affinity; more adverse events |
| Bortezomib (+ R-CHOP) — REMoDL-B | No overall PFS/OS benefit over R-CHOP | Molecular subtyping benefit not confirmed; added neuropathy without broad efficacy gain |
Choosing the right endpoint
Primary endpoints that matter in diffuse large b-cell lymphoma (dlbcl) trials
- Overall survival (OS) — Gold standard in a potentially curable disease; key for frontline registration
- Progression-free survival (PFS) — Primary endpoint of POLARIX; captures durable disease control
- Complete response (CR) rate — Central for single-arm relapsed trials (CAR-T, bispecifics); PET-negative CR predicts durability
- Event-free survival (EFS) — Used in second-line CAR-T trials (ZUMA-7, TRANSFORM) capturing need for new therapy
- Duration of response (DoR) — Distinguishes deep durable remissions from transient responses in R/R settings
How iNGENū runs diffuse large b-cell lymphoma (dlbcl) trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Diffuse Large B-Cell Lymphoma (DLBCL) clinical trials — FAQs
What is the standard first-line treatment for DLBCL?
What options exist if DLBCL relapses after chemoimmunotherapy?
What are bispecific antibodies in DLBCL?
Ready to discuss your diffuse large b-cell lymphoma (dlbcl) trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal